Skip to content

Effect of Turmeric-Boswellia formulation on subjects with mild to moderate osteoarthritis.

A randomized double-blinded placebo-controlled study to determine the efficacy of Turmeric-Boswellia formulation on subjects with mild to moderate osteoarthritis. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/059301
Enrollment
100
Registered
2023-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Turmeric-Boswellia extract: Turmeric-Boswellia extract in sesame oil (Rhuleave-K) 500mg once daily for 12 weeks Control Intervention1: Placebo: Polysorbate 80, PEG 400 500 mg once da

Sponsors

Arjuna Natural Private Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male or female 18 to 70 years of age with 1:1 ratio NRS score greater than or equal to 5 pain at the time of screening. BMI 18-29kg/m2. WOMAC score for Pain - 2 or more for any two activities. Stiffness – 1 or more for any one activity. Physical function – sub score 10 or more. Doctor diagnosed OA of knee – with Kellgren–Lawrence classification grades 2-3.

Exclusion criteria

Exclusion criteria: History of underlying back pain, all kinds of inflammatory arthropathy and rheumatoid arthritis, severe osteoarthritis, fibromyalgia, gout and history of knee surgery within the past 6 months, expectations of surgery in the next 4 months, hyaluronic acid alone or along with Intra-articular corticosteroid injections within the preceding 3 months. BMI greater than or equal to 30. High alcohol intake ( greater than 2 standard drinks per day). Smoking status not more than 1 pack per day. Psychotic tendencies such as schizophrenia, taking any psychotropic medicines. Psychedelic or narcotic substance use. Co-morbid illnesses such as cardiovascular, endocrine, renal or other chronic disease or limit normal function. Concomitant medications antibiotics, NSAIDS, steroids, OTC pills and ointments for pain 1 week, taking any kind of supplements for joint pain before screening. Any serious acute or chronic medical condition that in the judgment of the investigator would make it inappropriate for the subject to participate in this study. Positive pregnancy, breast feeding, pregnancy planning. Subjects who have not participated in a similar investigation in the past three months.

Design outcomes

Primary

MeasureTime frame
Change in womac total scoreTimepoint: Baseline, day 5, weeks 6 & 12.

Secondary

MeasureTime frame
Change in OARSI performance-based tests scoreTimepoint: Baseline, day 5, weeks 6 & 12.;Change in present pain intensity as measured using NRS scaleTimepoint: Baseline, day 5, weeks 6 & 12.;Change in range of motion as measured by goniometry scoreTimepoint: Baseline, day 5, weeks 6 & 12.

Countries

India

Contacts

Public ContactSooraj Rajasekharan Kartha

Arjuna Natural Pvt Ltd

drbinu@arjunanatural.com09447818432

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026